About the Study

VX-659 + Tezacaftor + Ivacaftor - A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Clinical Site Contact Information

Anne Arundel Medical Center
Annapolis,, MD
USA

Principal Investigator
Principal Investigator
Francisco Schopfer,

fjs2@pitt.edu.test
(718) 908-0987

Book an appointment